BeOne Medicines Ltd. American Depositary Shares

Zymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio o...

Molecular Partners AG announced its Annual General Meeting scheduled for April 14, 2026, and nominated Clare Fisher, SVP of Global Business Development and M&A at BeOne Medicines, to join its Board of Directors. Current board member Steven H. Holtzman will not seek re-election after 12 years of service. Fisher brings over two decades of healthcar...

Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeO...

The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated non-small cell lung cancer patients. The drug will undergo complete review with a PDUFA goal action date of November 14, 2026. Phase 3 trial data showed ivonescimab demonstrated improved overall survival compar...

Zymeworks Inc. announced that its management will participate in multiple investor conferences in February and March 2026, including Citi's Virtual Oncology Leadership Summit, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Citizens Life Science Conference. The company continues to advance its portfolio of licensed heal...